{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:56:51Z","timestamp":1791475011813,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ahj.2021.09.014","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T07:53:04Z","timestamp":1633333984000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes"],"prefix":"10.1016","volume":"243","author":[{"given":"Yang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard L.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-0171","authenticated-orcid":false,"given":"Marco","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-5958","authenticated-orcid":false,"given":"Catherine M","family":"Clase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.09.014_bib0001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Euro heart J Cardiovasc pharmacotherap"},{"key":"10.1016\/j.ahj.2021.09.014_bib0002","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0003","first-page":"S1","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Disease","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ahj.2021.09.014_bib0004","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Euro J heart fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"Nilsson","year":"2017","journal-title":"Int J cardiol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin proceed"},{"issue":"22","key":"10.1016\/j.ahj.2021.09.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.09.014_bib0008","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Euro J heart fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-020-01659-x","article-title":"Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care","volume":"18","author":"Bidulka","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2021.09.014_bib0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced ckd and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0011","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA internal medicine"},{"key":"10.1016\/j.ahj.2021.09.014_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gfv346","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2021.09.014_bib0013","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"The American journal of managed care"},{"key":"10.1016\/j.ahj.2021.09.014_bib0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jchf.2019.07.010","article-title":"Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality","volume":"7","author":"Beusekamp","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ckj\/sfv117","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness","volume":"9","author":"Runesson","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2021.09.014_bib0016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0017","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ckj\/sfaa242","article-title":"Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them","volume":"14","author":"Fu","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2021.09.014_bib0018","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0019","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ejhf.1371","article-title":"Clinical and research implications of serum versus plasma potassium measurements","volume":"21","author":"Cooper","year":"2019","journal-title":"Euro J heart fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0020","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Euro J heart fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0021","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management (CG182) 2015; https:\/\/www.nice.org.uk\/guidance\/cg182."},{"key":"10.1016\/j.ahj.2021.09.014_bib0022","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J cardiac fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0023","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2021.09.014_bib0024","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ckj\/sfaa242","article-title":"Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them","volume":"14","author":"Fu","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2021.09.014_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1742-7843.2006.pto_329.x","article-title":"Comparison of dynamic treatment regimes via inverse probability weighting","volume":"98","author":"Hernan","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ahj.2021.09.014_bib0026","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1212","article-title":"When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data","volume":"6","author":"Cain","year":"2010","journal-title":"Int J Biostat"},{"key":"10.1016\/j.ahj.2021.09.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","author":"Trevisan","year":"2021","journal-title":"Euro J heart fail"},{"key":"10.1016\/j.ahj.2021.09.014_bib0028","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfy283","article-title":"Merits and caveats of propensity scores to adjust for confounding","volume":"34","author":"Fu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ahj.2021.09.014_bib0029","article-title":"An introduction to inverse probability of treatment weighting in observational research","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2021.09.014_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ahj.2021.09.014_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10157-006-0458-z","article-title":"Clinical utility of trace proteinuria for microalbuminuria screening in the general population","volume":"11","author":"Konta","year":"2007","journal-title":"Clin exp nephro"},{"key":"10.1016\/j.ahj.2021.09.014_bib0032","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2021.09.014_bib0033","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.12834","article-title":"Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners","volume":"7","author":"Abensur Vuillaume","year":"2020","journal-title":"ESC heart failure"},{"key":"10.1016\/j.ahj.2021.09.014_bib0034","first-page":"904","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1016\/j.ahj.2021.09.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012818","article-title":"Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study","volume":"7","author":"Schmidt","year":"2017","journal-title":"BMJ open"},{"key":"10.1016\/j.ahj.2021.09.014_bib0036","article-title":"Patterns of chronic and transient hyperkalemia and clinically-important outcomes in patients with chronic kidney disease","author":"Trevisan","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2021.09.014_bib0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2014","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ahj.2021.09.014_bib0038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of Patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the amethyst-dn randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2021.09.014_bib0039","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ahj.2021.09.014_bib0041","series-title":"Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)","year":"2019"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:28Z","timestamp":1762077508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S0002870321002441"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.09.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}